![A deep learning-based iterative digital pathology annotation tool](https://immunitybio.com/wp-content/uploads/2021/11/bioRxiv.jpg)
![A deep learning-based iterative digital pathology annotation tool](https://immunitybio.com/wp-content/uploads/2021/11/bioRxiv.jpg)
![Preliminary data from QUILT 3.055: a phase 2 multi-cohort study of N803 (IL-15 superagonist) in combination with Checkpoint Inhibitors (CPI)](https://immunitybio.com/wp-content/uploads/2019/01/journal-1.jpg)
Preliminary data from QUILT 3.055: a phase 2 multi-cohort study of N803 (IL-15 superagonist) in combination with Checkpoint Inhibitors (CPI)
![PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations](https://immunitybio.com/wp-content/uploads/2022/01/img-logo-area-344x194-large.png)
PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations
![PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations](https://immunitybio.com/wp-content/uploads/2022/01/img-logo-area-344x194-large.png)
Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist.
![Overcoming hypoxia-induced functional suppression of NK cells](https://immunitybio.com/wp-content/uploads/2020/04/pub-med.jpg)